GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
6

60 Degrees Pharmaceuticals SXTP · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.47

-6.36%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

60 Degrees Pharmaceuticals — daily SXTP Delayed
Market value
$50,332
Last close × shares
Volume
51.3k
Shares, 20 Nov 2026

About 60 Degrees Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

60 Degrees Pharmaceuticals is based in Washington, Washington, DC and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SXTP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.0m and a net loss of $7.4m. At that date it held total assets of $5.4m and shareholders' equity of $3.5m.

In its own words

We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

60 Degrees Pharmaceuticals, Inc. is a Delaware corporation that was incorporated on June 1, 2022. On June 1, 2022, 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company (“60P LLC”), entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost-basis equal to $1,200.00 per share.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

More about 60 Degrees Pharmaceuticals →

Latest on 60 Degrees Pharmaceuticals

Our reporting

We have not reported on 60 Degrees Pharmaceuticals yet.

Next results

29 Mar 2027

Due on 29 Mar 2027. Analysts expect earnings of -0.67 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is 60 Degrees Pharmaceuticals's ticker?

60 Degrees Pharmaceuticals trades as SXTP on its US listing, under ISIN US83006G5009.

What was 60 Degrees Pharmaceuticals's last closing price?

0.47 on 20 Nov 2026. The figure is in USD and is never converted.

When does 60 Degrees Pharmaceuticals next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.